Canadian drug developer Medicago said on Tuesday it had started a late-stage study of its experimental COVID-19 vaccine combined with a booster from GlaxoSmithKline.
The study plans to enroll 30,000 participants and is initially focused on healthy adults, followed by those over 65 and those with the underlying disease.
Medicago, which has Canada’s most advanced COVID-19 vaccine project under development, expects to report results from a mid-stage trial of the vaccine in April.
The Medicago vaccine uses a technology known as virus-like particles, which mimic the structure of the coronavirus but contain no genetic material from it.
Its vaccines can be stored at normal refrigerator temperatures, between 2 C and 8 C, providing logistical benefits.
In phase one of its clinical trials, 100 percent of people who received its COVID-19 vaccine developed significant antibody responses with no severe adverse effects.
The phase 3 trial is expected to involve 30,000 people in 11 countries — including Canada — and will ultimately determine if the vaccine protects people from COVID-19.
The vaccine requires two doses, 21 days apart, and if approved by Health Canada, could be in the arms of Canadians by the second half of this year.
In March, the federal government announced it would fund Medicago’s COVID-19 vaccine efforts.
Seven months later, the federal government signed an agreement worth up to $173 million to accelerate Medicago’s vaccine development, secure doses, and complete the manufacturing plant.
This content is also available in: Tiếng Việt